The experimental mRNA vaccine is about 84 percent effective against the sometimes-deadly virus.
was 83.7 percent effective at preventing at least two symptoms, such as cough and fever, in adults 60 and older.
“RSV significantly affects the health of older and high-risk adults, particularly those with comorbidities,” Abdullah Baqui, a principal investigator for the study sites in Bangladesh and professor at Johns Hopkins Bloomberg School of Public Health, said . “This trial will help to understand the role of severe acute respiratory infections in older adult populations and inform the future implementation of vaccines in adults in lower-resource areas.”The study was conducted in roughly 37,000 participants age 60 and older and the data analysis was performed after 64 of the participants contracted the virus.
“Today’s results represent an important step forward in preventing lower respiratory disease due to RSV in adults 60 years of age and older. These data are encouraging, and represent the second demonstration of positive phase 3 trial results from our mRNA infectious disease vaccine platform after, Spikevax, our COVID-19 vaccine.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Moderna says its RSV vaccine is 84% effective in older adultsModerna announced positive results from its late-stage RSV vaccine trial in older adults.
Read more »
Moderna says RSV vaccine is 84% effective at preventing disease in older adultsRSV infections kill between 6,000 and 10,000 older adults every year and result in 60,000 to 120,000 hospitalizations, according to the CDC.
Read more »
Moderna says RSV vaccine 84% effective at preventing symptoms in older adultsModerna Inc said on Tuesday that its experimental messenger RNA vaccine for respiratory syncytial virus (RSV) was 83.7% effective in a late-stage trial at preventing at least two symptoms, such as cough and fever, in adults aged 60 and older.
Read more »
Moderna Reports RSV Vaccine Cuts Risk of Respiratory Diseases in Older AdultsAn RSV vaccine that Moderna is developing significantly reduced the risk of respiratory diseases in a key study, the company said
Read more »
Moderna’s RSV Shot Prevents Most Cases in Older PeopleModerna Inc.’s vaccine against RSV was highly effective in preventing the lung disease in older people, paving the way for the company to seek its first...
Read more »
Moderna says its RSV vaccine for older adults is 84% effective at preventing serious illnessModerna announced Tuesday its RSV vaccine for older adults was about 84% effective at preventing severe disease and the company plans to ask the FDA for approval in 2023.
Read more »